Skip to Main Content

Paper Details

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
3
2023
Advanced Non-Small-Cell Lung Cancer, Gefitinib, Iressa, NSCLC, Patients, ZD1839, advanced NSCLC, advanced non-small-cell lung cancer, diarrhea, epidermal growth factor receptor, gefitinib, patients, platinum, skin reactions, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Giuseppe GiacconeFrom the Kinki University School of Medicine, Osaka City University School of Medicine, Tokushima University School of Medicine, National Cancer Center, Central Hospital, and Japanese Foundation for Cancer Research, East Hospital, Kanagawa Cancer Center, and National Shikoku Cancer Center, France University Hospital Gasthuisberg, South Africa Academic Hospital Free University, United Kingdom and Vall d'Hebron University Hospital
Giuseppe GiacconeFrom the Kinki University School of Medicine, Osaka City University School of Medicine, Tokushima University School of Medicine, National Cancer Center, Central Hospital, and Japanese Foundation for Cancer Research, East Hospital, Kanagawa Cancer Center, and National Shikoku Cancer Center, France University Hospital Gasthuisberg, South Africa Academic Hospital Free University, United Kingdom and Vall d'Hebron University Hospital
José BaselgaFrom the Kinki University School of Medicine, Osaka City University School of Medicine, Tokushima University School of Medicine, National Cancer Center, Central Hospital, and Japanese Foundation for Cancer Research, East Hospital, Kanagawa Cancer Center, and National Shikoku Cancer Center, France University Hospital Gasthuisberg, South Africa Academic Hospital Free University, United Kingdom and Vall d'Hebron University Hospital
  • 1 - 3

Datasets

Release 1.2